Skip to content

The Evaluation of Chenopodium Formosanum and Fagopyrum Esculentum Extract on Anti-aging Effect

The Evaluation of Chenopodium Formosanum and Fagopyrum Esculentum Extract on Anti-aging Effect

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04237818
Enrollment
50
Registered
2020-01-23
Start date
2020-02-01
Completion date
2020-08-15
Last updated
2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Condition

Brief summary

To assess Chenopodium Formosanum and Fagopyrum Esculentum Extract on skin anti-aging

Interventions

DIETARY_SUPPLEMENTPlacebo drink

consume 2 bottle (30 mL) per day for 56 days

DIETARY_SUPPLEMENTChenopodium Formosanum and Fagopyrum Esculentum Extract drink

consume 2 bottle (30 mL) per day for 56 days

Sponsors

TCI Co., Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy adults aged between 20-65 years old * Subjects must read and sign the informed consent form after the study has been fully explained. * Subjects are willing to cooperate and comply with all of the regulation during the trial. * Subject should inform to investigator immediately if adverse effect is happened. * Subjects are willing to avoid UV overexposure during the trial (include indoor tanning treatment).

Exclusion criteria

* Subjects who have known cosmetic, drug or food allergies. * Subjects who have severe desquamation, tattoo, sunburn, peeling skin or other skin condition might impact measurement. * Subjects with any physical condition judged by the researcher not to be eligible for this study. * Subjects with uncontrollable physical condition such as high blood pressure, thyroid disease, diabetes, etc. * Female who is pregnant or nursing or planning to become pregnant during the course of the study. * Those who are currently participating in other clinical trials or who have just concluded a clinical trial two weeks ago. * Women who have started contraceptive or change current hormone contraceptive methods within 3 months.

Design outcomes

Primary

MeasureTime frameDescription
The change of skin L*a*b* valueChange from Baseline skin L*a*b* value at 8 weeksColor Spectrophotometer SCM-104/108 is utilized to measure skin L\*a\*b\* value. Units: arbitrary units
The change of skin elasticityChange from Baseline skin elasticity at 8 weeksCutometer® dual MPA 580 is utilized to measure skin elasticity (parameter R2). Units: μm penetration depth into the probe opening, expressed as curves
The change of skin wrinklesChange from Baseline skin wrinkles at 8 weeks3D Full-Face Skin Analyzer IRV is utilized to measure wrinkles. Units: arbitrary units
The change of skin collagen densityChange from Baseline skin collagen density at 8 weeksDermaLab® combo - 20 MHz High Freq. Ultrasound probe is utilized to scan and analyze skin collagen density. Units: Intensity score
The change of skin toneChange from Baseline skin tone at 8 weeks3D Full-Face Skin Analyzer IRV was utilized to measure skin tone. Units: arbitrary units
The change of skin brightnessChange from Baseline skin brightness at 8 weeks3D Full-Face Skin Analyzer IRV is utilized to measure skin brightness. Units: arbitrary units
The change of skin melanin indexChange from Baseline skin melanin index at 8 weeksMexameter® MX 18 is utilized to measure skin melanin index. Units: arbitrary Mexameter® units (0-999)
The change of skin moistureChange from Baseline skin moisture at 8 weeksCorneometer® CM825 is utilized to measure skin moisture. Units: arbitrary Corneometer® units 0-120

Secondary

MeasureTime frameDescription
The change of skin textureChange from Baseline skin texture at 8 weeks3D Full-Face Skin Analyzer IRV is utilized to measure skin texture. Units: arbitrary units
The change of skin poresChange from Baseline skin pores at 8 weeks3D Full-Face Skin Analyzer IRV is utilized to measure skin pores. Units: arbitrary units
The change of skin spotsChange from Baseline skin spots at 8 weeks3D Full-Face Skin Analyzer IRV is utilized to measure skin spots. Units: arbitrary units
The change of skin erythema levelChange from Baseline skin erythema level at 8 weeksMexameter® MX 18 is utilized to measure skin erythema level. Units: arbitrary Mexameter® units (0-999)
Self-assessment questionnaire8 weeksQuestionnaire is utilized to assess skin condition of the subjects. Units: score
The change of transepidermal water loss (TEWL)Change from Baseline TEWL at 8 weeksTewameter® TM 300 is utilized to measure transepidermal water loss. Units: g/hm²

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026